磷酸氟达拉滨（NSC-312887）用于晚期子宫内膜癌患者的II期研究。一项西南肿瘤学组研究。
Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer. A Southwest Oncology Group Study.
作者信息
Von Hoff D D, Green S, Alberts D S, Stock-Novack D L, Surwit E A, Miller T P, Stephens R L
机构信息
University of Texas Health Science Center, San Antonio.
出版信息
Am J Clin Oncol. 1991 Jun;14(3):193-4. doi: 10.1097/00000421-199106000-00004.
Abstract
Nineteen evaluable patients with advanced endometrial cancer refractory to one prior chemotherapeutic regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicity was grade 2 or greater leukopenia in 45% of patients. Fludarabine phosphate at this dose and schedule does not appear to be an active agent for patients with refractory endometrial cancer.
摘要
19例对一种先前化疗方案难治的晚期子宫内膜癌患者接受了为期5天的磷酸氟达拉滨治疗。未观察到缓解情况。主要毒性是45%的患者出现2级或更严重的白细胞减少。在此剂量和疗程下，磷酸氟达拉滨对难治性子宫内膜癌患者似乎不是一种有效的药物。
Zotero 插件